Evidence map›Paper›PMID 40590679›Full record

ArticleImmunotherapy2025

Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report.

Chao Han, Sujuan Xi, Te Shi, Haiyan Yue

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chao HanDepartment of Gastroenterology, Naval Medical Center, Naval Medical University, Shanghai, China.
Sujuan XiDepartment of Gastroenterology, Naval Medical Center, Naval Medical University, Shanghai, China.
Te ShiDepartment of Gastroenterology, Naval Medical Center, Naval Medical University, Shanghai, China.
Haiyan YueDepartment of Gastroenterology, Naval Medical Center, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colitis is a common adverse event in patients treated with immune checkpoint inhibitor (ICI). Additionally, virus infections pose an increased risk during ICI therapy. Corticosteroids is the cornerstone in treatment for ICI-related colitis. We herein report a case that includes detailed endoscopic and pathological findings of a patient diagnosed with advanced non-small cell lung cancer who was co-infected with HBV and EBV and demonstrated significant improvement after treatment with oral methylprednisolone. Given the widespread use of ICI, physicians should be vigilant regarding various adverse events, and patients should be monitored closely during treatment with ICI. Endoscopic and pathological evaluation insights into the management of ICI-related colitis.

Indexed as

Carcinoma, Non-Small-Cell LungCoinfectionColitisEpstein-Barr Virus InfectionsHepatitis BImmune Checkpoint InhibitorsLung NeoplasmsHepatitis B virusHerpesvirus 4, HumanHumansMethylprednisoloneImmune Checkpoint InhibitorsMethylprednisolonecase reportcolitisImmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapylung cancer

Identifiers

PMID40590679
PMCPMC12269705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.